Cel-Sci Corp. (CVM)
XASE:CVM
Want to see CVM full AI Analyst Report?
CVM Stock Chart & Stats
$5.19
-$0.03(-7.92%)
At close: 4:00 PM EST
$5.19
-$0.03(-7.92%)
Day’s Range― - ―
52-Week Range$0.89 - $13.48
Previous Close$0.36
Volume1.47M
Average Volume (3M)125.69K
Market Cap
$21.59M
Enterprise Value$17.20M
Total Cash (Recent Filing)$1.89M
Total Debt (Recent Filing)$8.51M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.47
Shares Outstanding14,493,111
10 Day Avg. Volume66,836
30 Day Avg. Volume125,686
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-17.94
Enterprise Value/Ebitda-0.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial PartnershipA revenue‑sharing distribution and regulatory/marketing partnership with Amarox creates a tangible commercialization pathway in a large, underserved regional market. Structurally this can accelerate regulatory coordination, de‑risk market entry execution, and provide non‑US revenue optionality if extended to the GCC.
GMP Manufacturing CapabilityOwning GMP bioprocessing facilities and offering CDMO services diversifies income beyond drug approval events. Durable manufacturing revenues can fund operations, support partner projects, and create asset‑based competitive advantages in cell and gene therapy supply chains over the medium term.
Moderate Historical LeverageHistorically moderate debt ratios relative to many precommercial biotech peers imply lower fixed interest burdens and greater financing flexibility. This structural leverage profile can preserve the company's ability to raise capital or enter partnership arrangements without immediate solvency pressure.
Bears Say
Pre-revenue ProfileAbsence of product revenue and sustained large net losses mean the business remains entirely dependent on clinical and regulatory progress for commercialization. This creates persistent execution risk: until Multikine or other assets generate sales, the company lacks self‑sustaining revenue streams.
Ongoing Cash BurnConsistent negative operating and free cash flow with multi‑year burn constrains runway and strategic optionality. Absent durable service contracts or milestone payments, the company will repeatedly require external funding, which can delay development timelines and limit investment in pivotal programs.
Dependence On External FinancingA business model reliant on equity or securities issuance for funding is structurally vulnerable to market conditions and dilution. Long‑term stability depends on securing partnerships, non‑dilutive funding, or eventual product approvals to replace recurring capital raises with operating cash flow.
Cel-Sci News
CVM FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was $0.89 and its highest was $13.48 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is $21.59M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is Aug 17, 2026 which is in 75 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on May 18, 2026. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.67.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 14,493,111 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -$0.67 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 20.28%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in CVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cel-Sci Corp.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Technical Analysis
Ownership Overview
4.25% Insiders
2.22% Mutual Funds
0.05% Other Institutional Investors
91.81% Public Companies and
Individual Investors